CD19 and neoplasm: Genetic mutations in CD19 developed in the majority of resistant tumor cells and irreversible loss of heterozygosity at the time of CD19-negative relapse [47], indicating that mutation of target antigen under selective pressure is one of the crucial mechanisms underlying antigen loss.